secwatch.observer — SEC 8-K summary
======================================

Issuer:     GRI Bio, Inc. (GRI)
CIK:        0001824293
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001824293-23-000145
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GRI Bio reports Q2 net loss of $8.9M, cash $4.8M, Phase 2a IPF study on track for H2 2023
--------------------------------------------------------------------------------

- Net loss of $8.9M for six months ended June 30, 2023, primarily from increased R&D and G&A expenses.
- Cash and equivalents $4.8M at June 30, 2023; merger with Vallon Pharmaceuticals closed.
- R&D expenses Q2 2023: $0.9M (up from $0.1M); G&A $5.1M (up from $0.1M) due to merger costs.
- Phase 2a biomarker study for GRI-0621 in IPF on track to launch in H2 2023.
- IND-enabling studies for GRI-0803 in SLE ongoing; IND filing expected in H1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824293/000182429323000145/0001824293-23-000145-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824293/000182429323000145/val-20230814.htm
  HTML page:      https://secwatch.observer/filing/0001824293-23-000145

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer